AbbVie puts $2B on the table for I-Mab cancer collab as biotech nabs $418M raise
It’s a good day for Shanghai-based I-Mab, which has penned a $2 billion upfront-biobucks R&D deal with AbbVie while also nabbing $418 million from investors.
It’s a good day for Shanghai-based I-Mab, which has penned a $2 billion upfront-biobucks R&D deal with AbbVie while also nabbing $418 million from investors.
Scorching temperatures fuel fires, threaten rolling blackouts around state
Lawsuit claims Trump administration changed schedule to exclude people from being counted
Gold futures ended lower for a third straight session on Friday, logging a weekly loss of around 2%, as better-than-expected monthly U.S. employment data helped to strengthen the U.S. dollar.
Nikkei declines slightly; SMIC shares plunge in Hong Kong after threat of U.S. export restrictions
To help meet the relentless demand for COVID-19 diagnostics, Thermo Fisher Scientific has stood up a new, $40 million manufacturing facility in six weeks.
The Trump administration has cut short its COVID-19 ventilator contract with Philips before a majority of the order could be delivered to the national stockpile.
A real-world trial of younger children with Type 1 diabetes showed that a closed-loop artificial pancreas system from Tandem Diabetes Care could help increase the amount of time spent each day within a healthy blood sugar range, including overnight as they slept.
Ionis Pharmaceuticals has struck a deal to buy its lipid disorder spinout Akcea Therapeutics. The deal will see Ionis pay around $500 million to acquire the 24% of Akcea that it doesn’t already own.
2019 was not a good year for Gilead’s fatty liver programs. Its lead prospect did worse than placebo in not one, but two, phase 3 studies, while its combination treatments also fell short in phase 2. It’s not letting those efforts go to waste, though—in studies presented at this year’s virtual International Liver Congress, Gilead and partner PathAI suggest improvements to NASH drug development.